Literature DB >> 22855389

The absence of PspA or presence of antibody to PspA facilitates the complement-dependent phagocytosis of pneumococci in vitro.

Bing Ren1, Jie Li, Kristopher Genschmer, Susan K Hollingshead, David E Briles.   

Abstract

Pneumococcal surface protein A (PspA) is a surface molecule on pneumococci that is required for full virulence in mouse models of infection. PspA has been reported to inhibit complement deposition on the pneumococcal surface. It has been assumed that this decreased complement deposition results in the inefficient phagocytosis of wild-type pneumococci. However, an effect of PspA on phagocytosis had not been shown. Our present studies demonstrated that a loss of PspA by capsular type 3 strains WU2 and A66.1 led to enhanced complement-dependent phagocytosis of the pneumococci by the mouse macrophage cell line J774A.1. This observation was made using human complement as well as mouse complement. Since this enhanced phagocytosis could be blocked by antibody to complement receptor CR3 on J774A.1, it was concluded that PspA's effect on phagocytosis was due to its effect on the amount of deposited complement, which in turn helped opsonize the pneumococci for phagocytosis. Since these studies included new independent mutants lacking PspA, the results provide solid confirmation of the previously reported effects of PspA on pneumococcal virulence and complement deposition. Finally, we showed that antibody to PspA, which is also known to enhance complement deposition, also enhances the phagocytosis of pneumococci in a largely complement-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22855389      PMCID: PMC3485889          DOI: 10.1128/CVI.00393-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  51 in total

Review 1.  Pattern recognition receptors: doubling up for the innate immune response.

Authors:  Siamon Gordon
Journal:  Cell       Date:  2002-12-27       Impact factor: 41.582

2.  Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H.

Authors:  C Neeleman; S P Geelen; P C Aerts; M R Daha; T E Mollnes; J J Roord; G Posthuma; H van Dijk; A Fleer
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  Truncated forms of PspA that are secreted from Streptococcus pneumoniae and their use in functional studies and cloning of the pspA gene.

Authors:  J Yother; G L Handsome; D E Briles
Journal:  J Bacteriol       Date:  1992-01       Impact factor: 3.490

4.  Complement receptor 1 expression on mouse erythrocytes mediates clearance of Streptococcus pneumoniae by immune adherence.

Authors:  Jie Li; Jennifer P Wang; Ionita Ghiran; Anna Cerny; Alexander J Szalai; David E Briles; Robert W Finberg
Journal:  Infect Immun       Date:  2010-05-03       Impact factor: 3.441

5.  Complete genome sequence of a virulent isolate of Streptococcus pneumoniae.

Authors:  H Tettelin; K E Nelson; I T Paulsen; J A Eisen; T D Read; S Peterson; J Heidelberg; R T DeBoy; D H Haft; R J Dodson; A S Durkin; M Gwinn; J F Kolonay; W C Nelson; J D Peterson; L A Umayam; O White; S L Salzberg; M R Lewis; D Radune; E Holtzapple; H Khouri; A M Wolf; T R Utterback; C L Hansen; L A McDonald; T V Feldblyum; S Angiuoli; T Dickinson; E K Hickey; I E Holt; B J Loftus; F Yang; H O Smith; J C Venter; B A Dougherty; D A Morrison; S K Hollingshead; C M Fraser
Journal:  Science       Date:  2001-07-20       Impact factor: 47.728

6.  Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae.

Authors:  Priya Balachandran; Alexis Brooks-Walter; Anni Virolainen-Julkunen; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

7.  Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae.

Authors:  H Y Wu; M H Nahm; Y Guo; M W Russell; D E Briles
Journal:  J Infect Dis       Date:  1997-04       Impact factor: 5.226

8.  Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection.

Authors:  Adriana T Moreno; Maria Leonor S Oliveira; Daniela M Ferreira; Paulo L Ho; Michelle Darrieux; Luciana C C Leite; Jorge M C Ferreira; Fabiana C Pimenta; Ana Lúcia S S Andrade; Eliane N Miyaji
Journal:  Clin Vaccine Immunol       Date:  2010-01-20

9.  Lipoprotein PsaA in virulence of Streptococcus pneumoniae: surface accessibility and role in protection from superoxide.

Authors:  Jason W Johnston; Lisa E Myers; Martina M Ochs; William H Benjamin; David E Briles; Susan K Hollingshead
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

10.  Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection.

Authors:  Richard Malley; Philipp Henneke; Sarah C Morse; Michael J Cieslewicz; Marc Lipsitch; Claudette M Thompson; Evelyn Kurt-Jones; James C Paton; Michael R Wessels; Douglas T Golenbock
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-04       Impact factor: 11.205

View more
  24 in total

1.  Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies.

Authors:  Míriam A da Silva; Thiago R Converso; Viviane M Gonçalves; Luciana C C Leite; Martha M Tanizaki; Giovana C Barazzone
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

Review 2.  Pathogens penetrating the central nervous system: infection pathways and the cellular and molecular mechanisms of invasion.

Authors:  Samantha J Dando; Alan Mackay-Sim; Robert Norton; Bart J Currie; James A St John; Jenny A K Ekberg; Michael Batzloff; Glen C Ulett; Ifor R Beacham
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

3.  Viability and virulence of pneumolysin, pneumococcal surface protein A, and pneumolysin/pneumococcal surface protein A mutants in the ear.

Authors:  Patricia A Schachern; Vladimir Tsuprun; Sarah Goetz; Sebahattin Cureoglu; Steven K Juhn; David E Briles; Michael M Paparella; Patricia Ferrieri
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2013-09       Impact factor: 6.223

4.  A pneumococcal vaccine combination with two proteins containing PspA families 1 and 2 can potentially protect against a wide range of Streptococcus pneumoniae strains.

Authors:  Jinfei Yu; Xiaorui Chen; Bo Li; Tiejun Gu; Xiangyu Meng; Wei Kong; Yongge Wu
Journal:  Immunol Res       Date:  2018-08       Impact factor: 2.829

5.  Modified opsonization, phagocytosis, and killing assays to measure potentially protective antibodies against pneumococcal surface protein A.

Authors:  Calvin C Daniels; Kyung-Hyo Kim; Robert L Burton; Shaper Mirza; Melissa Walker; Janice King; Yvette Hale; Patricia Coan; Dong-Kwon Rhee; Moon H Nahm; David E Briles
Journal:  Clin Vaccine Immunol       Date:  2013-08-07

6.  Correlation between in vitro complement deposition and passive mouse protection of anti-pneumococcal surface protein A monoclonal antibodies.

Authors:  Naeem Khan; Raies Ahmad Qadri; Devinder Sehgal
Journal:  Clin Vaccine Immunol       Date:  2014-11-19

7.  A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).

Authors:  Kristopher R Genschmer; Mary Ann Accavitti-Loper; David E Briles
Journal:  Vaccine       Date:  2013-11-06       Impact factor: 3.641

8.  Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles.

Authors:  Shannon L Haughney; Latrisha K Petersen; Amy D Schoofs; Amanda E Ramer-Tait; Janice D King; David E Briles; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Acta Biomater       Date:  2013-06-14       Impact factor: 8.947

9.  Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholine.

Authors:  Reshmi Mukerji; Shaper Mirza; Aoife M Roche; Rebecca W Widener; Christina M Croney; Dong-Kwon Rhee; Jeffrey N Weiser; Alexander J Szalai; David E Briles
Journal:  J Immunol       Date:  2012-10-26       Impact factor: 5.422

Review 10.  Rationale and prospects for novel pneumococcal vaccines.

Authors:  Kristin Moffitt; Richard Malley
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.